Ozempic and Nicotine: What You Need to Know About This Interaction

Is there a direct interaction between Ozempic and nicotine?

Ozempic (semaglutide) is a GLP-1 receptor agonist injected once weekly to treat type 2 diabetes [1]. Its drug interactions section addresses two things: insulin and insulin secretagogues such as sulfonylureas, because of hypoglycemia risk, and other oral medicines, because semaglutide slows gastric emptying [1]. Nicotine, tobacco and nicotine replacement products are not among them [1].

There is no metabolic reason to expect a clash either. Semaglutide is broken down by proteolytic cleavage of its peptide backbone and beta-oxidation of its fatty acid side chain rather than by CYP enzymes, and it has very low potential to inhibit or induce CYP enzymes [1]. Nicotine is a CYP2A6 substrate [2]. The two drugs do not share an elimination route.

The smoking warning you may have heard does not apply here

Smoking does change how the body handles a long list of medicines, but not through nicotine. Polycyclic aromatic hydrocarbons in tobacco smoke induce the liver enzyme CYP1A2; nicotine itself is not the inducer [3][5]. Quitting smoking, with or without nicotine replacement, can raise blood levels of CYP1A2 substrates as the enzyme de-induces [4].

Reviews name caffeine, clozapine, olanzapine and theophylline as the main CYP1A2 interactions, and one review found dose adjustment clearly indicated for warfarin, olanzapine, clozapine and theophylline [5][4]. In one study of 12 heavy smokers who stopped abruptly, caffeine clearance fell 36.1% to a new steady state, and the apparent half-life of the CYP1A2 activity decrease was 38.6 hours [6].

Semaglutide is not cleared by CYP1A2, so the enzyme change after quitting smoking is not expected to alter its levels through that pathway [1]. Nicotine replacement does not prevent that enzyme shift [4].

Heart rate, blood pressure and blood vessels

Nicotine constricts peripheral blood vessels and raises heart rate and blood pressure, and tolerance does not develop to its catecholamine-releasing effects [3]. Smoking also blunts the blood-pressure and heart-rate lowering that beta-blockers produce [3].

The Ozempic label carries no heart-rate warning, and it does not address nicotine's cardiovascular effects during treatment [1].

Semaglutide has been tested for cardiovascular outcomes. In SUSTAIN-6, 3,297 adults with type 2 diabetes, 83% with established cardiovascular disease, chronic kidney disease, or both, took semaglutide 0.5 mg or 1 mg weekly or placebo for 104 weeks. The combined endpoint of cardiovascular death, non-fatal heart attack or non-fatal stroke occurred in 6.6% versus 8.9% (hazard ratio 0.74, 95% CI 0.58 to 0.95) [7].

Stomach effects and pancreatitis

Semaglutide delays gastric emptying, and the label warns about severe gastrointestinal reactions, stating that the drug is not recommended in people with severe gastroparesis [1]. In the pooled placebo-controlled Ozempic trials, nausea occurred in 6.1% on placebo, 15.8% on 0.5 mg and 20.3% on 1 mg; any gastrointestinal reaction in 15.3%, 32.7% and 36.4%; and 0.4%, 3.1% and 3.8% stopped treatment for gastrointestinal reasons [1]. Most nausea, vomiting and diarrhea reports came during dose escalation [1].

The label also warns about acute pancreatitis and says to discontinue Ozempic if pancreatitis is suspected [1]. Separately, smoking is an independent risk factor for acute and chronic pancreatitis [8].

Is nicotine replacement different from cigarettes?

On the cardiovascular side, yes. Nicotine from patches and gum reaches the blood more slowly and usually at a lower dose than nicotine from cigarette smoke, and smoke carries many cardiovascular toxins other than nicotine [10]. Smoking increases blood coagulability, which transdermal nicotine does not appear to do [10]. A review of nicotine's cardiovascular toxicity concluded that at worst the risk from nicotine replacement is no greater than from smoking, and that trials in stable coronary disease suggest nicotine itself does not raise cardiovascular risk [10].

Labels still carry cautions. The Nicotrol nasal spray label says to weigh risks in patients with cardiovascular or peripheral vascular disease, and to evaluate carefully in coronary heart disease, serious arrhythmias or vasospastic disease.

What nicotine replacement does not change is the liver enzyme shift after quitting, which is attributed to the smoke rather than the nicotine [4].